GRCE · Grace Therapeutics, Inc.
Market Cap
$44.18M
Shares
21.04M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-13 | — | |
| 10-Q | 2026-08-13 | 2026-06-30 | |
| 8-K | 2026-08-06 | 2026-08-04 | |
| 8-K | 2026-07-28 | — | |
| DEF 14A | 2026-07-28 | 2026-09-17 | |
| 10-K | 2026-06-18 | 2026-03-31 | |
| 8-K | 2026-06-18 | — | |
| 8-K | 2026-06-18 | — | |
| 8-K | 2026-06-05 | 2026-06-01 | |
| 8-K | 2026-04-27 | — | |
| 8-K | 2026-04-23 | — | |
| 8-K | 2026-02-12 | — | |
| 10-Q | 2026-02-12 | 2025-12-31 | |
| 8-K | 2026-01-12 | 2026-01-10 | |
| 10-Q/A | 2025-11-17 | 2025-09-30 | |
| 8-K | 2025-11-13 | — | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-10-23 | — | |
| 8-K | 2025-09-18 | — | |
| 8-K | 2025-09-12 | — | |
| 8-K | 2025-08-27 | — | |
| 8-K | 2025-08-12 | — | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| DEF 14A | 2025-07-28 | 2025-09-12 | |
| 8-K | 2025-06-25 | — | |
| 8-K | 2025-06-23 | — | |
| 10-K | 2025-06-23 | 2025-03-31 | |
| 8-K | 2025-04-09 | — | |
| 8-K | 2025-03-03 | — | |
| 10-Q/A | 2025-02-19 | 2024-12-31 | |
| 10-Q | 2025-02-13 | 2024-12-31 | |
| 8-K | 2025-02-13 | — | |
| 8-K | 2025-02-10 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-10-28 | 2024-10-24 | |
| 8-K | 2024-10-25 | — | |
| 8-K | 2024-10-07 | 2024-10-01 | |
| 8-K | 2024-09-30 | — | |
| 8-K | 2024-09-25 | — | |
| 8-K | 2024-08-16 | 2024-08-12 | |
| 8-K | 2024-08-09 | — | |
| 10-Q | 2024-08-09 | 2024-06-30 | |
| 8-K | 2024-06-27 | — | |
| 10-K | 2024-06-21 | 2024-03-31 | |
| 8-K | 2024-06-21 | — | |
| 8-K | 2024-04-01 | — | |
| 10-Q | 2024-02-12 | 2023-12-31 | |
| 8-K | 2024-02-12 | — | |
| 8-K | 2024-01-08 | 2024-01-05 |
Showing 1–50 of 136 filings
Key facts
CIK
1444192
CUSIP
00439U104
13F (30d)
27 filings
27 filers
Visit website
Investor relations